title: Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients.
abstract: OBJECTIVE
  We describe the prevalence, risk factors and outcome of hyperlactataemia (HL) in a cohort of 140 HIV-infected patients.
  
  
  METHODS
  Patients were enrolled consecutively within a 3-month period (July to September 1999) and followed until 31 October 2000. One hundred and forty HIV-infected patients had venous plasma lactate levels measured. HL was defined at baseline by two consecutive lactate levels > 2.1 mmol/L (upper limit of normal). We compared baseline demographic characteristics, immuno-virological parameters, antiretroviral therapy and outcome between patients with HL (cases) or without HL (controls). We described the clinical features of patients with HL.
  
  
  RESULTS
  Among 129 patients included in the analysis, HL was found in 11 patients (8.5%), all of whom were receiving nucleoside reverse transcriptase inhibitors (NRTIs). Cases were more likely than controls to receive didanosine or stavudine (82% vs. 19%, P= 2.7 x 10(-6) and 82% vs. 48%, P= 0.03, respectively). Only 4/11 cases (36%) had symptoms consistent with HL. After a median follow-up of 15 months, lactate level returned to normal in all three patients who discontinued NRTIs, but in only 2/8 patients who did not (P = 0.06). Only one case experienced lactic acidosis and died during follow-up. Mortality rate was similar in cases and controls.
  
  
  CONCLUSIONS
  HL is associated with NRTI use, in particular didanosine and stavudine, and discontinuation of NRTIs seems to be associated with rapid resolution of HL. Lactic acidosis remains rare and the long-term outcome of patients with HL does not seem to be poorer than controls.
authors.affiliation: Clinique des Maladies Infectieuses, Département de Biostatistique et Informatique Médicale, Laboratoire de Biochimie B, Hôpital Saint-Louis, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Hocqueloux
authors.forename: C
authors.initials: C
authors.lastname: Alberti
authors.forename: J-P
authors.initials: JP
authors.lastname: Feugeas
authors.forename: M
authors.initials: M
authors.lastname: Lafaurie
authors.forename: E
authors.initials: E
authors.lastname: Lukasiewicz
authors.forename: G
authors.initials: G
authors.lastname: Bagnard
authors.forename: O
authors.initials: O
authors.lastname: Carel
authors.forename: D
authors.initials: D
authors.lastname: Erlich
authors.forename: J-M
authors.initials: JM
authors.lastname: Molina
mesh_terms: D000140:Acidosis, Lactic / Q000139:chemically induced; D000328:Adult; D019380:Anti-HIV Agents / Q000009:adverse effects; D016049:Didanosine / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D019344:Lactic Acid / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects; D012307:Risk Factors; D018119:Stavudine / Q000009:adverse effects
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019344:Lactic Acid; D018119:Stavudine; D016049:Didanosine